Drug firm BDR Pharmaceuticals on Friday said it plans to launch 400 mg Favipiravir tablets, used for treating COVID-19 patients, in the country. The ‘BDFAVI’ 400 mg tablets will be priced at Rs 990 for a strip of 10 tablets, BDR Pharma said in a statement. Each tablet will cost Rs 99.

In August, the company launched 200 mg Favipiravir tablets. “We aim to make BDFAVI available in sufficient quantities to meet the high demand for the drug in the Indian market to help curb the current crisis… introducing a higher dosage is an attempt to ensure a smoother experience to patients and caregivers,” BDR PharmaCMD Dharmesh Shah said.

The companyhad received approval from the Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat patients with mild to moderate COVID-19 symptoms under the brand name BDFAVI, according to the statement.

BDR Group of companies has grown steadily and become a house-hold name in the pharmaceutical Industry over the last 15 years, in both domestic and international arenas. They are recognized as a “niche” player in manufacturing of Pharmaceutical APIs and for our renowned new age formulations. The group is complemented majorly by its two companies - BDR Pharmaceuticals International Pvt Ltd and BDR Life sciences Pvt. Ltd, each one having stamped its own supremacy in respective fields, i.e. API and formulation manufacturing, respectively.

BDR Group focuses on development in 4 specialized therapeutic segments, viz. Oncology, Critical care, Gynecology & Neurology, which are its dream segments.

Over the years, BDR has built an undeniable reputation for its specialization in early identification, development and introduction of new molecules, in a continuous endeavor to make globally available high cost medicines to local masses at affordable prices;

Innovation and development are the inalienable cornerstones of BDR group. Investing heavily in R&D activities, possess state–of-the-art API and Formulation development centers accredited by the DSIR, Government of India. Our facilities are in a state of constant & continuous upgradation, so as to keep up and meet with the constantly growing demands of the dynamic International scenario. Blending of human skill and innovative expertise of BDR often acts as a catalyst for development of desired modern technology and setting up of world class facilities.

BDR‘s philosophy of sustained growth and consolidation is achieved by strategic tie-ups with several globally renowned players. Today, we can boast of having tie-ups with market leaders in almost all the strategically important emerging markets. We are proud recipient of “Golden Award for Best Exporter” from Pharmexcil (Export Promotion Council) consecutively since 2010.